​

Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MNPR Stock Forecast

Monopar Therapeutics (MNPR) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $79.00, with a high of $87.00 and a low of $70.00. This represents a 84.15% increase from the last price of $42.90.

- $18 $36 $54 $72 $90 High: $87 Avg: $79 Low: $70 Last Closed Price: $42.9

MNPR Stock Rating

Monopar Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 2 Hold (22.22%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 2 7 Strong Sell Sell Hold Buy Strong Buy

MNPR Price Target Upside V Benchmarks

TypeNameUpside
StockMonopar Therapeutics84.15%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts335
Avg Price Target$79.00$79.00$59.20
Last Closing Price$42.90$42.90$42.90
Upside/Downside84.15%84.15%38.00%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 25241--7
Aug, 25241--7
Jul, 25231--6
Jun, 25211--4
May, 25211--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 09, 2025Jeet MukherjeeBTIG$87.00$44.9393.63%102.80%
Sep 02, 2025Raymond James$80.00$33.93135.78%86.48%
Aug 26, 2025H.C. Wainwright$70.00$30.61128.68%63.17%
Nov 19, 2024Justin WalshUBS$37.00$19.0194.63%-13.75%
Nov 11, 2024Sean LeeH.C. Wainwright$22.00$15.8139.15%-48.72%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 09, 2025BTIGBuyinitialise
Sep 03, 2025OppenheimerOutperforminitialise
Sep 02, 2025Raymond JamesStrong Buyinitialise
Jan 10, 2025Piper SandlerOverweightinitialise
Oct 11, 2024Rodman & RenshawBuyinitialise
Aug 12, 2024H.C. WainwrightBuyBuyhold
Jan 28, 2021Roth CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-450 $-350 $-250 $-150 $-50 $50 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.58$-411.23----
Avg Forecast$-3.30$-1.29$-2.38$-1.48$0.53$1.86
High Forecast$-3.30$-1.26$-1.27$0.70$3.17$1.86
Low Forecast$-3.30$-1.31$-3.49$-3.95$-3.69$1.86
Surprise %-82.42%31778.29%----

Revenue Forecast

$10M $23M $36M $49M $62M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$14.52M$42.50M$70.72M
High Forecast---$14.52M$42.50M$70.72M
Low Forecast---$14.52M$42.50M$70.72M
Surprise %------

Net Income Forecast

$-20B $-15B $-10B $-5B $0 $5B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.40M$-15.59B----
Avg Forecast$-47.89M$-18.69M$-34.53M$-15.84M$-8.53M$26.99M
High Forecast$-47.89M$-18.35M$-18.42M$10.16M$46.00M$26.99M
Low Forecast$-47.89M$-19.03M$-50.65M$-57.32M$-53.55M$26.99M
Surprise %-82.45%83291.11%----

MNPR Forecast FAQ

Is Monopar Therapeutics stock a buy?

Monopar Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monopar Therapeutics is a favorable investment for most analysts.

What is Monopar Therapeutics's price target?

Monopar Therapeutics's price target, set by 9 Wall Street analysts, averages $79 over the next 12 months. The price target range spans from $70 at the low end to $87 at the high end, suggesting a potential 84.15% change from the previous closing price of $42.9.

How does Monopar Therapeutics stock forecast compare to its benchmarks?

Monopar Therapeutics's stock forecast shows a 84.15% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Monopar Therapeutics over the past three months?

  • September 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • July 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Monopar Therapeutics’s EPS forecast?

Monopar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.38, marking a -99.42% decrease from the reported $-411 in 2024. Estimates for the following years are $-1.48 in 2026, $0.53 in 2027, and $1.86 in 2028.

What is Monopar Therapeutics’s revenue forecast?

Monopar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $14.52M, followed by $42.5M for 2027, and $70.72M for 2028.

What is Monopar Therapeutics’s net income forecast?

Monopar Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-34.533M, representing a -99.78% decrease from the reported $-15.586B in 2024. Projections indicate $-15.836M in 2026, $-8.525M in 2027, and $26.99M in 2028.